

Attorney Docket Number O 98393 US

## IN THE CLAIMS:

1. (Currently amended) An isolated peptide ~~Peptide having an amino acid sequence~~ of 9-55 amino acids ~~acid residues~~ comprising the amino acid sequence FTLASAETT (SEQ ID NO: 1).
2. (Currently amended) An isolated peptide ~~Peptide having an amino acid sequence~~ of 13-55 amino acids ~~acid residues~~ comprising the amino acid sequence HSFTLASAETTVG (SEQ ID NO: 2)
3. (Currently amended) The peptide ~~Peptide~~ according to claim 1 having an amino acid sequence of 9 to 25 amino acid residues ~~acids~~.
4. (Currently amended) The peptide ~~Peptide~~ according to claim 1 consisting essentially of having the amino acid sequence FTLASAETT (SEQ ID NO: 1) or HSFTLASAETTVG (SEQ ID NO: 2).
5. Cancelled
6. (Previously amended) Pharmaceutical composition comprising at least one peptide according to claim 1 and a pharmaceutically acceptable carrier.
7. (Previously amended) A method for the manufacture of a pharmaceutical preparation for the induction of specific T-cell tolerance to an autoantigen in patients suffering from autoimmune disorders, comprising combining a peptide according to claim 1 with a pharmaceutically acceptable carrier.
8. (Previously amended) Diagnostic composition comprising at least one peptide according to claim 1 and a detection agent.

9. Cancelled

Attorney Docket Number O 98393 US

10. Cancelled

11. (Currently amended) The peptide ~~Peptide~~ according to claim 2 having an amino acid sequence of 13 to 25 amino acids ~~acid~~ ~~residues~~.

12. (Previously added) A method for detecting autoreactive T-cells comprising: providing peripheral blood mononuclear cells; culturing the peripheral blood mononuclear cells; incubating the peripheral blood mononuclear cells with at least one peptide according to claim 1; and detecting a response of the peripheral blood mononuclear cells to the presence of the peptide.

3

---

9-55 amino acids" comprising the specified amino acid sequence. It is believed that reciting a 9-55 amino acid peptide does not read on a product of nature.

Claims 9 and 10 stand rejected under 35 U.S.C. 112, first paragraph, for lack of enablement regarding the route of administration. Applicants traverse this rejection as the conventional routes of administration are well known to the ordinary practitioner. However, in order to advance the prosecution of this application, Applicants have cancelled claims 9 and 10 without prejudice to pursuing patent protection for those claims in a continuation application.

4

Attorney Docket Number O 98393 US


Claims 1-4, 6, 8 and 11 stand rejected under 35 U.S.C.

102 (b) for anticipation by Hu et al. Hu et al is said to teach the full length protein YKL-39 in a pharmaceutical composition and with a detection agent.

Applicants respectfully submit that the claims do not read on the full length protein disclosed by Hu et al. It is believed that with the present amendments, which clarify this fact, claims 1-4, 6-8 and 11-12 are in condition for allowance. Favorable action is solicited.

Should the Examiner consider that a conference would be helpful in advancing the prosecution of this application, he is invited to telephone Applicants' attorney at the number below.

Respectfully submitted,



William M. Blackstone  
Attorney for Applicants  
Registration Number 29,772

Akzo Nobel Patent Department  
Intervet Inc  
405 State Street  
P.O. Box 318  
Millsboro, DE 19966  
Tel: (410) 464-0581  
Sec. (302) 933-4027  
Fax: (302) 934-4305

OFFICIAL

FAX RECEIVED  
AUG 27 2003  
GROUP 1600